Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, despite their excellent therapeutic effect, these medications typically result in a broad spectrum of toxicity reactions. Immune-related cardiotoxicity is uncommon but can be potentially fatal, and its tru...

Descripción completa

Detalles Bibliográficos
Autores principales: Torrente, María, Blanco, Mariola, Franco, Fabio, Garitaonaindia, Yago, Calvo, Virginia, Collazo-Lorduy, Ana, Gutiérrez, Lourdes, Sánchez, Juan Cristóbal, González-del-Alba, Aranzazu, Hernández, Roberto, Méndez, Miriam, Cantos, Blanca, Núñez, Beatriz, Sousa, Pedro A. C., Provencio, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751318/
https://www.ncbi.nlm.nih.gov/pubmed/36531707
http://dx.doi.org/10.3389/fcvm.2022.1062858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751318/
https://www.ncbi.nlm.nih.gov/pubmed/36531707
http://dx.doi.org/10.3389/fcvm.2022.1062858

Ejemplares similares